In a statement Germany’s Federal Office for the Protection of the Constitution (BfV) said, China’s state backed hacking group APT 27 which since long is suspected of launching attacks on Western government agencies, is now targeting German companies in sectors… Read More ›
On Tuesday, Novartis raised the prospect of divesting its generic drugs unit Sandoz while revising upwards its revenue estimate for its two best-selling pharmaceuticals. “Novartis has commenced a strategic review of the Sandoz Division. The review will explore all options, ranging… Read More ›
On Friday German news magazine Der Spiegel reported German Economy Minister Peter Altmaier as saying, he wants to support pharmaceuticals companies that are dependent for key reagents on imports from Asia in order to rebuild their production sites in Europe…. Read More ›
The deal sees Britain’s AstraZeneca Plc led by Pascal Soriot sharing development and commercialization costs for the drug worldwide. For AstraZeneca the deal makes sense as it will replenish its pipeline as its cancer drug sales grow. In a significant… Read More ›
Ignyta’s precision drugs and diagnostic portfolio will help Roche increase its global footprint in the oncology department. On Friday, U.S. cancer drugmaker Ignyta Inc and Swiss drugmaker Roche disclosed that the Swiss pharmaceutical giant will acquire U.S. drugmaker for $1.7… Read More ›
The likelihood of the Republican tax bill undergoing change is high since the House tax bill aims to not only cut taxes, which by itself is hard, but is also taking on provisions that are specific to certain industries, which… Read More ›
While the deal will boost Ipen’s cancer drug portfolio, Merrimack’s shareholders will receive a special dividend as an outcome of the deal. France-based drug manufacturer Ipsen SA, has disclosed it will be acquiring some assets from its U.S. peer Merrimack… Read More ›
Without this divesture, there is likely to be reduced competition among vaccine manufacturers in the U.S. and EU. The divesture is key to their $13.5 billion deal. So as to streamline Boehringer Ingelheim acquisition of Sanofi, the German pharmaceutical maker… Read More ›
manageria.biz 